The new antibiotic, called pretomanid and developed by the nonprofit TB Alliance, achieved a 90 percent success rate among patients with drug-resistant TB.
By Zoe Rohrich
Fake pharmaceuticals are a multi-billion dollar problem around the world. Made and packaged to look like the real deal, these phonies may contain a fraction of the active ingredients or none at all. these fake drugs can have serious consequences…
By Fred de Sam Lazaro
When prescribing medications, caring for children poses a particular challenge. They’re not just little adults. Their still-developing brains and bodies metabolize drugs differently, and what works for grown-ups can yield radically different — and sometimes dangerous — results in kids.
By Shefali Luthra, Kaiser Health News
When Australian biotech firm Innate Immunotherapeutics needed to raise money last summer, it offered a sweetheart deal to “sophisticated U.S. investors.” One of them was Rep. Tom Price.
By Jay Hancock and Rachel Bluth, Kaiser Health News
By Sheila Kaplan, STAT
Trump's nominee to be secretary of health and human services, Rep. Tom Price, could have conflicts of his own.
By PBS NewsHour
After news broke that the price of EpiPen injectors has skyrocketed, the allergy medicine’s maker, Mylan, announced its intention to offer a generic version of the product, to be sold at half the market price of the original. The New…
By Philip Moeller
The absence of drug-pricing proposals from the GOP contenders illustrates how hard it would be for Sanders or Clinton to get Congressional approval should they win office.
By Michael Ollove, Stateline
As more expensive specialty drugs come on the market to treat some of the most serious chronic diseases, more states are stepping in to cushion the financial pain for patients who need medicine that can cost up to hundreds of…
By Richard Knox, NPR
A growing number of people who got infected in the 1960s through the 1990s have now "used up" the infection's latency period, notes Dr. Camilla Graham of Beth Israel Deaconess Hospital in Boston, "which is why we're now seeing this…
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.